Multifaceted aging and rapamycin
نویسنده
چکیده
Aging is commonly defined as a time-dependent loss of physiological integrity, leading to the decline and impair in organism functions and to the increase of risk for cancer and other major age-associated diseases, finally increasing vulnerability to death [1]. During the last decade the intensive search of anti-aging remedies has lead to the conclusion that both the insulin/IGF-like signaling (IIS) and nutrient response pathways such as the mechanistic target of rapamycin (MTOR) control aging and age-associated pathology in yeast, worms, insects and mammals [2-6]. mTOR complex 1 (mTORC1) is activated by insulin and related growth factors through phosphatidylinositol-3-OH kinase (PI(3)K) and AKT kinase signaling and suppressed by AMP-activated protein kinase (AMPK), a key sensor of cellular energy status. mTORC1 involved into promotion messenger RNA translation and protein synthesis through ribosomal protein S6 kinases (S6Ks) and 4E-BP protein, which in the hypophosphorylated form acts as a negative regulator of the cap-binding protein eIF4E. mTORC1 also stimulates lipid biosynthesis, inhibits autophagy, and through hypoxic response transcription factor HIF-1α regulates mitochondrial function and glucose metabolism. Rapamycin suppresses mTORC1 and also indirectly mTORC2 that leads glucose intolerance and abnormal lipid profile. Effects of biguanides and rapamycin on the senescence-associates secretory phenotype interfering with IKK-β/NF-κB – an important step in hypothalamic programming of systemic aging. Recent finding of suppressive effect of rapamycin on some parameters of brain aging in mice [7] and in senescence-accelerated OXYS rats [8] have shown that the drug controls multiple events related to aging. There are nine tentative hallmarks of aging in mammals, which may represent common denominators of aging in different organisms: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered cell-to-cell communication [1]. Rapamycin and metformin seem to influence all of them. Noteworthy, there is a significant similarity in the effects of rapamycin and metformin as anti-aging and anti-carcinogenic remedies. We believe that rapamycin Editorial
منابع مشابه
Progeria, rapamycin and normal aging: recent breakthrough
A recent discovery that rapamycin suppresses a pro-senescent phenotype in progeric cells not only suggests a non-toxic therapy for progeria but also implies its similarity with normal aging. For one, rapamycin is also known to suppress aging of regular human cells. Here I discuss four potential scenarios, comparing progeria with both normal and accelerated aging. This reveals further indication...
متن کاملRapamycin extends life- and health span because it slows aging
Making headlines, a thought-provocative paper by Neff, Ehninger and coworkers claims that rapamycin extends life span but has limited effects on aging. How is that possibly possible? And what is aging if not an increase of the probability of death with age. I discuss that the JCI paper actually shows that rapamycin slows aging and also extends lifespan regardless of its direct anti-cancer activ...
متن کاملRapamycin preserves gut homeostasis during Drosophila aging
Gut homeostasis plays an important role in maintaining the overall body health during aging. Rapamycin, a specific inhibitor of mTOR, exerts prolongevity effects in evolutionarily diverse species. However, its impact on the intestinal homeostasis remains poorly understood. Here, we demonstrate that rapamycin can slow down the proliferation rate of intestinal stem cells (ISCs) in the aging guts ...
متن کاملMathematical Modelling of Metabolic Regulation in Aging
The underlying cellular mechanisms that characterize aging are complex and multifaceted. However, it is emerging that aging could be regulated by two distinct metabolic hubs. These hubs are the pathway defined by the mammalian target of rapamycin (mTOR) and that defined by the NAD+-dependent deacetylase enzyme, SIRT1. Recent experimental evidence suggests that there is crosstalk between these t...
متن کاملRapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency
Comment on: 1. Komarova et al. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging. 2012; 4:10 2. Comas et al. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging.2012; 4;10.
متن کامل